Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)

March 15, 2019 updated by: National Institutes of Health Clinical Center (CC)

Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors

Background:

Zika virus is mostly passed on by the bite of an infected mosquito. It usually causes mild illness. But in pregnant women it can cause serious birth defects to the baby. The virus can also spread by blood transfusion and sexual intercourse. This is why the U.S. Food & Drug Administration (FDA) recommended that people should not give blood if possibly exposed to Zika virus. Dengue virus and chikungunya virus are passed by the same mosquitoes as Zika virus. These can cause severe reactions if passed through transfused blood.

Donated blood is usually not tested for these three viruses. Researchers want to count the infections in people who have been exposed because of travel or sexual exposure. They want to learn the risk these viruses might pose to the U.S. blood supply. They also want to study the natural history of these viruses by following infected people over time.

Objective:

To study the risk of Zika, dengue, and chikungunya viruses to the U.S. blood supply.

Eligibility:

Adults age 18 or older who were turned down for donating blood because of possible exposure to certain viruses.

Design:

Participants will have blood and urine tests. They will answer questions about their travel.

They will be called in about a week with virus test results.

Participants with negative results do not have any more study visits.

Participants with positive results will be asked to stay in the study for 6 months. They will have weekly clinic visits and tests until results are negative for 2 straight weeks. Once test results are negative, they will have monthly visits. Visits will include physical exams, blood and urine samples, and optional semen samples from men.

Most people will have 3-4 weekly visits and 5 monthly visits.

Study Overview

Status

Completed

Conditions

Detailed Description

Zika virus (ZIKV) is an Aedes species mosquito-transmitted Flavivirus responsible for an ongoing epidemic in over twenty countries and territories in the Caribbean, and in North, Central and South America. A 20-fold increased risk of microcephaly has been reported in newborns of infected mothers in Brazil. Of nine identified pregnant travelers returning to the U.S. from areas with local ZIKV infection, five have experienced severe neonatal outcomes.

ZIKV can be transmitted via blood transfusion and by sexual exposure to a ZIKV-infected man. In response, AABB (formerly the American Association of Blood Banks) made recommendations and the Food and Drug Administration (FDA) issued guidance for donor deferral based on 1) travel to locations with active ZIKV transmission; or for 2) sexual exposure to a man who has traveled to an area with active ZIKV transmission. Further, Aedes species mosquito vectors that transmit ZIKV also transmit dengue virus (DENV) and chikungunya virus (CHIKV). Areas with local ZIKV transmission also commonly have local DENV and CHIKV transmission. DENV and CHIKV are transmissible via blood transfusion and can result in severe outcomes in transfusion recipients.

The primary aims of this study are to: 1) assess the prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among adults who attempted to donate blood but were deferred because of travel to places with local transmission of ZIKV, DENV and/or CHIKV (travel-deferred donors); 2) assess the prevalence of ZIKV infection (RNA-positives) among adults who attempted to donate blood who were deferred due to potential sexual exposure to ZIKV infection; 3) assess the prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among blood donors whose blood or platelets were collected and who called back to report any illness within 2 weeks of donation; and to 4) study the 24-week natural history of ZIKV, DENV and CHIKV infection among deferred adult donors who tested RNA-positive for any of these agents.

Study Type

Observational

Enrollment (Actual)

34

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Institutes of Health Clinical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA:
  • Adults who traveled within the past month to places with local transmission of ZIKV, DENV and/or CHIKV who would otherwise be eligible to donate blood;
  • Volunteer adult blood donors or potential blood donors who are deferred from blood donation because they tested positive for Zika virus.

  • Volunteer adult blood and platelet donors (blood donors) who present to the NIH Clinical Center Department of Transfusion Medicine (DTM) and the Fishers Lane Donor Center are eligible for study enrollment if they:

    1. Are deferred because of travel to an area with active ZIKV transmission within the past 4 weeks; or
    2. Are deferred because of sexual contact during the past 4 weeks with a sexual partner who traveled to an area with active ZIKV transmission in the 3 months prior to that instance of sexual contact; or
    3. Are deferred because of travel to a malaria-endemic area; and returned from the area in the past month; or
    4. Have donated blood or platelets AND within 2 weeks of donation they called the NIH DTM or Fishers Lane Donor Centers to report any signs or symptoms of infection, AND they traveled to an area with active transmission of ZIKV, DENV or CHIKV within the past 4 weeks (from symptom onset); OR had sexual contact within the past 4 weeks (from symptom onset) with a sexual partner who traveled to an area with active ZIKV transmission in the 3 months prior to that instance of sexual contact.

EXCLUSION CRITERIA:

Potential donors who do not meet the inclusion criteria are excluded. Potential donors under 18 years of age, paid or research blood donors and pregnant women are excluded from enrollment. Children are not eligible to donate blood without parental consent and the frequency of number of follow-up visits places an undue burden on school age children. Paid or research blood donors are not representative of the normal blood donor population. Pregnant women are not eligible to donate blood.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among travel-deferred adult blood donors in the study population.
Time Frame: Time 0; among RNA-positives: weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24
Time 0; among RNA-positives: weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24
Prevalence of ZIKV infection (RNApositives) among adult blood donors with a history of potential sexual exposure to ZIKV infection, in the study population.
Time Frame: Time 0; among RNA-positives: weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24
Time 0; among RNA-positives: weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24
24-week Natural History of ZIKV, DENV and CHIKV (RNA-positives).
Time Frame: weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24
weeks 1,2,3,4,5,6,7,8,9,10,11,12,16,20,24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institutes of Health Clinical Center (CC)

Investigators

  • Principal Investigator: Robert D Allison, M.D., National Institutes of Health Clinical Center (CC)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 8, 2016

Primary Completion (Actual)

March 14, 2019

Study Completion (Actual)

March 14, 2019

Study Registration Dates

First Submitted

June 8, 2016

First Submitted That Met QC Criteria

June 8, 2016

First Posted (Estimate)

June 9, 2016

Study Record Updates

Last Update Posted (Actual)

March 18, 2019

Last Update Submitted That Met QC Criteria

March 15, 2019

Last Verified

March 14, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 160124
  • 16-CC-0124

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dengue Virus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe